Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEOGet Free Report) has been given a consensus recommendation of “Buy” by the six analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last year is $20.80.

Several equities research analysts have recently commented on the company. Stifel Nicolaus assumed coverage on Lexeo Therapeutics in a report on Tuesday, November 28th. They issued a “buy” rating and a $20.00 price objective for the company. Royal Bank of Canada initiated coverage on shares of Lexeo Therapeutics in a research report on Tuesday, November 28th. They set an “outperform” rating and a $22.00 target price for the company. Chardan Capital began coverage on Lexeo Therapeutics in a research report on Tuesday, November 28th. They set a “buy” rating and a $23.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Lexeo Therapeutics in a research report on Tuesday, November 28th. Finally, SVB Leerink initiated coverage on shares of Lexeo Therapeutics in a research report on Tuesday, November 28th. They issued an “outperform” rating and a $19.00 price objective on the stock.

Get Our Latest Stock Report on Lexeo Therapeutics

Lexeo Therapeutics Trading Down 3.7 %

Shares of NASDAQ:LXEO opened at $15.93 on Tuesday. The stock’s fifty day moving average is $15.08. Lexeo Therapeutics has a 12 month low of $9.00 and a 12 month high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEOGet Free Report) last posted its earnings results on Monday, December 11th. The company reported ($12.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($11.40). Equities analysts expect that Lexeo Therapeutics will post -4.52 EPS for the current fiscal year.

Lexeo Therapeutics Company Profile

(Get Free Report

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.

Read More

Analyst Recommendations for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.